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Cold inducible RNA-binding protein (CIRP) is a nuclear protein which has been recently
identified as a novel inflammatory mediator in hemorrhagic shock and sepsis. We hypothesized
that CIRP acts as a potent inflammatory mediator in hepatic ischemia-reperfusion (I/R), and thus
blocking CIRP protects against I/R-induced liver injury. Male C57BL/6 mice were subjected to
70% hepatic ischemia by microvascular clamping of the hilum of the left and median liver lobes
for 60 min, followed by reperfusion. Anti-CIRP antibody (1 mg/kg body weight) or vehicle
(normal saline) in 0.2 mL was injected via the internal jugular vein at the beginning of the
reperfusion. Blood and liver tissues were collected 24 h after I/R for various measurements and a
10-day survival study was performed. CIRP released into the circulation was significantly
increased 24 h after hepatic I/R. Anti-CIRP antibody treatment markedly reduced hepatocellular
damage markers and significantly improved the liver microarchitecture. Anti-CIRP also reduced
the systemic and local inflammation demonstrated by attenuation in both serum and hepatic levels
of interleukin 6. The expression of neutrophil-attracting chemokine as well as liver neutrophil
infiltration was reduced by anti-CIRP treatment. Anti-CIRP also dramatically decreased the
amount of apoptosis and nitrosative stress, evidenced by decrease in TUNEL staining and
inducible nitric oxide synthase and cyclooxygenase-2 levels, respectively. Finally, the 10-day
survival rate was increased from 37.5% in the vehicle group to 75% in the anti-CIRP treatment
group. Thus, targeting CIRP offers potential therapeutic implications in the treatment of hepatic
I/R injury.
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Hepatic ischemia-reperfusion (I/R) injury can occur in a variety of clinical settings that
include but not limited to trauma, liver resections, orthotopic transplantation, or prolonged
shock states (1, 2). In the setting of liver transplantation, hepatic I/R contributes up to 10%
of early organ failure as well as creating a higher incidence of both acute and chronic
rejection (3). There is a multifarious interaction between hepatocytes, sinusoidal endothelial
cells, and Kupffer cells as well as infiltrating neutrophils, macrophages, and platelets. The
proinflammatory signaling mediators on all of these cell types become activated as a
consequence of tissue anoxia and are further exacerbated upon reperfusion (1). Many
attempts have been made to apply pharmacologic therapies or modify surgical approaches to
reduce or help protect against hepatic I/R injury with limited success (4, 5). Therefore,
identification of novel targets for developing therapeutic interventions to treat liver I/R
injury is still under intensive research.
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In the clinic, it would be challenging to protect against the ischemic damage in advance.
After its occurrence, one can explore only a few avenues to help alleviate the hepatic I/R
injury. One way is to reduce the milieu of inflammation, which is a major contributing factor
to the injury. The inflammatory response associated with hepatic I/R is considered as a
sterile type, which is not triggered by bacterial infection (6, 7). Such an inflammatory
reaction is in response to the free radicals generated from acute oxidative and nitrosative
stress during I/R (6). Another initiation of sterile inflammation is caused by the release of
endogenous damage-associated molecular patterns (DAMPs) from host cells during injury
(6-8). DAMPs can interact with pattern-recognition receptors, such as toll-like receptor
(TLRs) and receptors of advanced glycation end products (RAGEs), in immune cells to
activate the NF-κB signaling pathway for proinflammatory cytokine release (7, 9)
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Cold-inducible RNA-binding protein (CIRP) is a 172-amino acid nucleoprotein that belongs
to the family of cold shock proteins (10, 11). It has one N-terminal consensus-sequence
RNA-binding domain and one C-terminal glycine-rich domain (10). CIRP is originally
identified to facilitate the translation by stabilizing mRNAs when cells are under certain
stressful circumstances, including hypothermia, exposure to ultraviolet irradiation, or
hypoxia (9, 11). Human CIRP mRNA is constitutively expressed in various cell lines from
different organ origins, including blood, liver, kidney, cervix, and urinary bladder (10).
However, the expression of CIRP in human tissues has not been reported yet, except our
recent study shown in serum (11). Recently, our laboratory identified that extracellular CIRP
acts as a DAMP to accentuate the inflammatory response through binding to TLR4 and
myeloid differentiation factor 2 (MD2) complex (11-13). Also, neutralizing antiserum to
CIRP attenuates the inflammatory response in the settings of hemorrhagic and septic shock
(11).
In our recent study, we have observed a significant increased CIRP expression in the liver of
rats which underwent hemorrhagic and septic shock (11). In this study, we hypothesized that
CIRP plays an important role in the pathogenesis of I/R-induced hepatic injury. To
investigate this, we used an established mouse model of hepatic I/R injury and first measure
the levels and kinetics of CIRP release in the serum after I/R. We then further examined the
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effect of anti-CIRP antibody treatment on organ damage, inflammatory response, neutrophil
infiltration, apoptosis, and oxidative stress. Finally, we evaluated the efficacy of anti-CIRP
antibody treatment on the survival of mice after being subjected to hepatic I/R injury.

Materials and Methods
Experimental animals
Adult male C57BL/6 mice (20-25g) from Charles River Laboratories (Wilmington, Mass)
were housed in a temperature controlled room on a 12-h light-dark cycle and fed a standard
laboratory diet. Upon acquisition, mice were allowed to acclimate to the environment in our
facility 5-7 days before the experiment. All mice were housed in cages of five members and
animals were fasted overnight before undergoing surgery, but allowed water ad libitum. All
experiments were performed in strict accordance with National Institute of Health guidelines
for the use of experimental animals, and this study approved by the Institutional Animal
Care and Use Committee of the Feinstein Institute for Medical Research.
Animal model of hepatic I/R
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Mice were randomly assigned to three groups; sham, vehicle (normal saline), or anti-CIRP
antibody treatment. Hepatic I/R was performed as described previously (2, 14). Briefly,
animals underwent induction of anesthesia with 2.5% inhalational isoflurane, after which the
ventral abdomen was shaved and cleansed with 10% povidone-iodine wash. A 3-4 cm
midline incision was performed, and the hilum of the liver was exposed, allowing for
identification of the hepatic artery and portal vein. A microvascular clip was placed across
the hilum of the left lateral and median lobes to produce 70% ischemia for 60 min. At the
beginning of the reperfusion, 0.2 mL normal saline, non-immunized control IgG (1 mg/kg
body weight, [BW]), or anti-CIRP antibody (1 mg/kg BW) (11) was injected via internal
jugular vein. We also administered anti-CIRP antibody at 10 mg/kg BW in our preliminary
study and found its effects not significantly different from 1 mg/kg BW. The neutralizing
polyclonal anti-CIRP antibody was generated as antisera against purified recombinant
murine CIRP from rabbits and the IgG fraction was isolated from antisera by immobilized
immunopure protein-A and -G chromatography as described previously by us (11). AntiCIRP antibody inhibits the TNF-α release in macrophages stimulated with CIRP in a dosedependent manner (11). After closure of the abdomen, 1 mL bolus of normal saline was
given i.p. and the anesthesia was withdrawn. After operation, 1.0% lidocaine was applied
topically to the surgical incision site and vein cannulation. Sham operated animals
underwent midline laparotomy alone, without hepatic ischemia or administration of any
treatments. Core body temperature was monitored throughout the entire operation and
maintained between 35.5°C to 37.0°C by the use of an indwelling rectal thermometer and a
heating pad placed below the animals. Blood and liver samples were collected 24 h after
ischemia and stored at -80°C before analysis.
Survival study
Following the process of hepatic I/R as described in the animal model, the remaining 30% of
the non-ischemic liver portion was resected at the onset of reperfusion. Then, normal saline
or anti-CIRP antibody (1 mg/kg BW) was injected via internal jugular vein. Without
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resection, most of the animals which underwent hepatic I/R will live with 30% functionally
non-ischemic liver for 10 days. The animals were then monitored daily to record the survival
time.
Western blotting analysis
Liver tissues (100 mg) were lysed and homogenized in 300 μL lysis buffer (10 mM Tris-HCl
pH 7.5, 120 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% sodium dodecyl
sulfate) containing a protease inhibitor cocktail (Roche Diagnostics, Indianapolis, Ind) using
a sonic dismembrator on ice. Samples were centrifuged at 14,000 revolutions/min for 15 min
at 4°C, and the supernatant collected. Following measurement of sample protein
concentration by BioRad DC protein assay kit (Bio-RAD, Hercules, Calif), 50 μg samples
were separated on 4% to 12% Bis-Tris gels and transferred to nitrocellulose membranes.
Membranes were incubated with primary antibody against CIRP or β-actin (SantaCruz
Biotechnologies, Santa Cruz, Calif). All protein bands were detected by species-specific
infrared fluorescence secondary antibodies (1:10,000) and analyzed by the LI-COR Odyssey
Fc Imager (LI-COR, Lincoln, Neb) and band intensity measured using the NIH Image J
densitometric software.
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Measurement of injury markers and interleukin 6 (IL-6)
Whole-blood samples were centrifuged at 4,000 revolutions/min for 12 min to collect serum.
The activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and
lactate dehydrogenase (LDH) in the serum were determined by assay kits from Pointe
Scientific (Lincoln Park, Mich). Serum and liver tissue IL-6 levels were determine by an
enzyme-linked immunosorbent assay (ELISA) kit specific for mouse IL-6 (BD Biosciences,
San Diego, Calif). These assays were carried out according to the manufacturer's
instructions.
qPCR analysis
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Total RNA was extracted from the liver by TRIzol reagent (Invitrogen, Carlsbad, Calif) and
was reverse-transcribed into cDNA using murine leukemia virus reverse transcriptase
(Applied Biosystems, Foster City, Calif). A PCR reaction was carried out in a 24 μL
containing 0.08 μmol of each forward and reverse primer, 2 μL cDNA, 9.2 μL H2O, and 12
μL SYBR Green PCR Master Mix (Applied Biosystems). Amplification was conducted in
an Applied Biosystems 7300 model under the thermal profile of 50°C for 2 min and 95°C
for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The level of mouse
β-actin mRNA was used for normalization and each specific mRNA was conducted in
duplicate. Relative expression of mRNA was calculated by the 2-ΔΔCt method, and results
were expressed as fold change in comparison to the sham group. The sequence of primers
for this study is listed as follows: IL-6, 5′-CCGGAGAGGAGACTTCACAG-3′ (forward)
and 5′-CAGAATTGCCATTGCACAAC-3′ (reverse); MIP-2, 5′CCCTGGTTCAGAAAATCATCCA-3′ (forward) and 5′GCTCCTCCTTTCCAGGTCAGT-3′ (reverse); iNOS, 5′GGCAAACCCAAGGTCTACGTT-3′ (forward) and 5′GAGCACGCTGAGTACCTCATTG-3′ (reverse); COX-2, 5′CTCAGCCAGGCAGCAAATC-3′ (forward) and 5′-ACATTCCCCACGGTTTTGAC-3′
Shock. Author manuscript; available in PMC 2016 January 01.
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(reverse); β-actin, 5′-CGTGAAAAGATGACCCAGATCA-3′ (forward) and 5′TGGTACGACCAGAGGCATACAG-3′ (reverse).
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Histological evaluation of liver injury and immunostaining for neutrophils
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Liver tissues were taken from the median lobe following 24 h of reperfusion and stored in
10% formalin before being fixed in paraffin. Samples were then sectioned to 4 μm cuts and
stained with hematoxylin–eosin (H&E). Liver parenchymal injury was then assessed in a
blinded fashion using a semi-quantitative light microscopy evaluation. The histologic injury
score for each sample was expressed as the sum of the individual scores given for five
different parameters; cytoplasmic color fading, cellular vacuolization, sinusoidal congestion,
necrosis, and erythrocyte stasis (15-17). Scores for each variable ranged from 0 (0%), to 1
(1%-10%), 2 (10%-30%), 3 (30%-60%), 4 (>60%), with a highest possible score of 20. Each
sample score was then averaged over 10 microscopic fields. For neutrophil staining,
paraffin-embedded liver tissues were dewaxed in xylene and rehydrated in a graded series of
ethanol. The slides were heated in 0.92% citric acid buffer (Vector Laboratories,
Burlingame, Calif) at 95°C for 30 min. After cooling, the slides were incubated with 2%
H2O2/60% methanol and blocked in normal rabbit serum/Tris-buffered saline. The anti-Gr-1
antibody (BioLegend, San Diego, Calif) was applied and incubated overnight. The detection
was carried out as per the instructions provided by an immunohistochemistry kit with
NovaRED substrate from Vector Laboratories.
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay
Apoptosis in liver tissue was identified by TUNEL assay using an In Situ Cell Death
Detection Kit (Roche). The assay was conducted according to the manufacturer's
instructions. The nucleus was stained with 4′,6-diamidino-2-phenylindole (DAPI).
Statistical analysis
All data are expressed as a mean ± SE and compared by one-way analysis of variance
(ANOVA) and the Student-Newman-Keuls (SNK) test. Survival rates were analyzed by the
Kaplan-Meier estimator and compared using a log-rank test. Differences in values were
considered significant if p < 0.05.
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Results
Circulating levels of CIRP are increased after hepatic I/R
To explore the role of CIRP as a potential inflammatory mediator in hepatic I/R, we
examined the release of CIRP in serum by Western blotting at 1, 4, and 24 h after the start of
the 60-min hepatic ischemia followed by reperfusion in mice. Serum CIRP was detectable in
sham, still comparable to sham at 1 h, increased by 2.6-fold at 4 h and significantly elevated
by 5.9-fold at 24 h after hepatic I/R (Fig. 1). These findings are consistent with our prior
studies of increased CIRP release in hemorrhagic shock and sepsis (11), suggesting that
CIRP plays an important role in triggering inflammatory responses in hepatic I/R as well.
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Anti-CIRP antibody treatment attenuates liver injury after hepatic I/R
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Serum levels of hepatic damage markers AST, ALT, and LDH were increased by 21-, 34and 62-fold, respectively, 24 h after hepatic I/R (Fig. 2A-C). With the administration of
neutralizing antibody against CIRP at the beginning of reperfusion, significant reduction
was seen in organ injury markers by 74%, 83%, and 68%, respectively (Fig. 2A-C).
However, the AST, ALT, and LDH levels in mice treated with non-immunized control IgG
(1 mg/kg BW) were comparable to the vehicle group (AST, 1501 ± 567 vs. 1509 ± 205
IU/L; ALT, 543 ± 200 vs. 573 ± 236 IU/L; and LDH, 3502 ± 1256 vs. 2762 ± 656 IU/L control IgG vs. vehicle). Further, these serum injury markers data correlated with the hepatic
tissue architecture damaged observed by histological evaluation. Histological alterations
seen in liver tissue samples 24 h after hepatic I/R were most evident for the degree of
necrosis, micro-hemorrhage, and leukocyte infiltration in vehicle-treated animals in
comparison to sham as well as anti-CIRP antibody-treated animals (Fig. 3A-C).
Quantification of liver histologic injury score after hepatic I/R showed that vehicle-treated
groups exhibited a 3.7-fold increase in severity compared to sham-operated animals, which
was significantly reduced by 48% in anti-CIRP antibody-treated animals (Fig. 3D). Taken
together, these results demonstrate that anti-CIRP antibody administration provides
significant protection against liver injury from hepatic I/R.
Anti-CIRP antibody treatment inhibits the inflammatory response after hepatic I/R
To ascertain the systemic and local inflammatory responses to hepatic I/R in our model, IL-6
levels were measured in both serum and liver tissue 24 h after hepatic I/R. Vehicle-treated
animals showed an increase in serum IL-6 levels by 63-fold compared to sham group. When
animals were administered anti-CIRP antibody, this increase in IL-6 levels was significantly
reduced by 75% (Fig. 4A). In the liver tissue IL-6 protein levels increased by 2-fold in the
vehicle-treated group compared to sham group, and anti-CIRP antibody treatment decreased
it by 44% (Fig. 4B). Also, IL-6 mRNA increased by 18-fold in vehicle in comparison to
sham, which was decreased by 94% in anti-CIRP treated group (Fig. 4C). Thus, anti-CIRP
antibody administration resulted in downregulation of both systemic as well as local levels
of proinflammatory marker IL-6.
Anti-CIRP antibody treatment reduces neutrophil infiltration into the liver after hepatic I/R
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Hepatic I/R also results in overproduction of local proinflammatory chemokines, so we
checked the expression of macrophage inflammatory protein 2 (MIP-2) in the liver tissue.
The MIP-2 mRNA levels determined by qPCR dramatically increased by 179-fold in
vehicle-treated mice compared to sham mice. However, MIP-2 levels were reduced by 80%
in anti-CIRP antibody-treated group compared to vehicle group (Fig. 5A). Chemokines such
as MIP-2 mediate tissue infiltration of neutrophils which release deleterious inflammatory
mediators causing liver injury. To determine the degree of neutrophil infiltration associated
with hepatic I/R, we performed immunohistochemistry staining of liver tissue for
granulocyte receptor 1 (Gr-1), which is a marker for neutrophils. There is an abundance of
neutrophils seen in vehicle group compared to sham, with a drastic reduction in anti-CIRP
antibody-treated animals (Fig. 5B-D). Together, this data suggests that anti-CIRP antibody
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administration not only reduces proinflammatory chemokines, but also decreases associated
neutrophil recruitment to the liver.
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Anti-CIRP antibody treatment decreases apoptosis after hepatic I/R
To examine whether anti-CIRP antibody treatment has any effect on apoptosis after hepatic
I/R, we performed TUNEL assay which detects DNA fragmentation resulting from
apoptosis, in the liver tissues 24 h after hepatic I/R. There were no TUNEL-positive cells
(green spots) in the sham livers (Fig. 6A), but vehicle treated animals showed very
prominent TUNEL-positive areas (Fig. 6B). After anti-CIRP antibody treatment there is a
significant decline in TUNEL-positive areas in comparison to vehicle treated animals (Fig
6C). Taking into account the H&E staining which showed necrosis, not apoptosis, in the
majority of the hepatocellular damage, primary role of anti-CIRP antibody in hepatic I/R
may not be protection from apoptosis, but reduction in apoptosis could be a secondary
benefit.
Anti-CIRP antibody treatment reduces nitrosative stress after hepatic I/R

NIH-PA Author Manuscript

To determine the effect of anti-CIRP antibody treatment on the oxidative stress associated
with hepatic I/R, we evaluated the liver tissue levels of iNOS and COX-2 at 24 h after
hepatic I/R. We observed a 7.9-fold increase in iNOS mRNA expression in liver tissue of
vehicle-treated I/R animals when compared to sham group, which was significantly reduced
by 86% in anti-CIRP antibody-treated animals (Fig. 7A). COX-2 mRNA levels were also
increased by 173-fold in vehicle treated group in comparison to sham, with a drastic
reduction by 99% in anti-CIRP antibody-treated animals (Fig. 7B).
Anti-CIRP antibody treatment improves survival following a lethal model of hepatic I/R
To evaluate the potential survival benefit of neutralizing CIRP with anti-CIRP antibody, we
used a total hepatic I/R model as previously described (2). We observed that only 37.5% of
vehicle treated animals survived for 10 days after being subjected to hepatic I/R with
subsequent partial hepatectomy of the non-ischemic portions of the liver. Whereas, the 10day survival rate under these conditions increased significantly to 75% in the anti-CIRP
antibody treated group (Fig. 8). Thus, anti-CIRP antibody treatment doubled the survival
rate of mice after hepatic I/R compared to vehicle controls.
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Discussion
CIRP is a member of the family of cold shock proteins that respond to cold stresses by
functioning as RNA chaperone to promote translation giving a survival advantage (10).
However, our previous study has established that CIRP can be released and acts as a DAMP
to induce inflammatory responses (9, 11). We have also shown that neutralizing antisera to
CIRP attenuates inflammatory responses and improves the survival of hemorrhagic and
septic animals (11). The purpose of the current study is to test the hypothesis that CIRP can
also act as a mediator of inflammation and injury in hepatic I/R. Indeed, we find that CIRP
levels increase in the serum in a time dependent manner after hepatic I/R. In particular, we
show that blockade of CIRP protects against hepatic I/R injury with a decrease in systemic
and local hepatic proinflammatory cytokine expression. We also demonstrate that blockade
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of CIRP not only prevents the I/R associated neutrophil infiltration into the liver but also
results in reduced hepatocyte apoptosis and oxidative stress. Finally, we reveal that
administration of neutralizing antisera to CIRP significantly reduces the mortality rate to
half in a lethal model of hepatic I/R.
Hepatic I/R injury has been shown to affect the function of multiple organ systems and
cause systemic consequences (18, 19). Because hepatic I/R injury is seen in a variety of
clinical settings and liver dysfunction creates such serious complications leading to possibly
death, it makes this a topic for extensive research. The current understanding of the
pathophysiology of hepatic I/R consists of complex interactions of multiple inflammatory
pathways with the main contributors being from the production of reactive oxygen species,
release of proinflammatory cytokines and chemokines, as well as the activation of immune
cells that promote inflammation and tissue damage (20). The immune response generated
during hepatic I/R lacks a microbial component, but instead is initiated by endogenous self
proteins or DAMPs (6, 8). Although we did not examine the damage of other organs in this
study, we expect there will be a systemic effect on other organs due to the elevation of CIRP
in serum after hepatic I/R to induce inflammatory responses.
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The extracellular delivery of DAMPs depends on their production by injured cells and the
extent of the tissue injury (21). Activation of the immune system, specifically the innate
immune cells by DAMPs has been under investigation for the past two decades. TLRs are
pattern recognition receptors located both intra- and extra-cellularly, but differ from each
other in ligand specificity, expression patterns, and in some instances signaling pathways
(22-24). Recently, TLR4 has been revealed to play a pivotal role in multiple I/R models and
its antagonism can attenuate the inflammatory response in I/R involving the heart, liver, and
kidney (22, 25). Some DAMPs bind to the TLR4-MD2 complex on the surface of
monocytes, macrophages, and neutrophils to generate a cytokine storm leading to damaging
effect that is preceded by an ischemic insult (26).
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CIRP has been found to be constitutively expressed in low amounts in various tissues and its
expression is up regulated during cellular stress (11, 12, 27). The human CIRP gene has
been mapped to chromosome locus 19p13.3 and is 95.3% identical to the amino-acid
sequence to that of mouse CIRP (10). The redistribution of CIRP is not only attributed to
necrosis, but it is also actively secreted from macrophages. The release of CIRP is not
through the classical endoplasmic reticulum – Golgi apparatus, but through a lysosomal
secretions process (11). This extracellular CIRP causes an induction of TNF-α, IL-6, and
high-mobility group box 1(HMGB1) expression via engaging the TLR4-MD2 complex and
activation of the NF-κB pathway (11, 27). Whether CIRP can suppress the production of
anti-inflammatory cytokines needs further investigation. We believe that our study is first to
report that CIRP plays a role in the generation of sterile inflammatory response in hepatic
I/R. We found that serum CIRP levels increase in a time-dependent manner after hepatic
I/R. Such increase is associated with the elevation of proinflammatory mediators IL-6 and
MIP-2, and hepatocellular damage. These proinflammatory mediators drive neutrophils
infiltrating the liver, which can exacerbate oxidative liver damages at the later stage of
reperfusion (6). With administration of anti-CIRP antibody, the levels of local and systemic
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IL-6 as well as liver MIP-2 expression are decreased, which is associated with the reduction
of neutrophil infiltration and hepatocellular damage.
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In addition, anti-CIRP antibody administration also decreases the cellular oxidative stress
which plays an important role in the cellular damage during I/R injury (28). Upregulation of
iNOS in I/R injury causes excessive production of nitric oxide which reacts with superoxide
anion (O2-), creating peroxynitrite (ONOO-). Peroxynitrite then contributes to injury through
lipid peroxidation, apoptosis, necrosis, and neutrophil recruitment by nitration of tyrosine
residues on tissue proteins (29). Indeed, we observe that anti-CIRP antibody administration
decreases the expression of iNOS and COX-2 as well as apoptosis in the liver after I/R. We
believe this to be significant as previous studies have demonstrated that apoptosis is a key
contributor to injury following hepatic I/R and that therapies aimed at reducing apoptosis
have proven to be hepatoprotective (30). However, the initial I/R injury caused by reactive
oxygen species, leading to activation of an inflammatory cascade and resulting in an
increase of both apoptosis and necrosis (29, 31). There is a varying degree in the literature
debating whether the primary mode of cell death in hepatic I/R is apoptosis or necrosis, and
since apoptosis is an energy depended process necrosis should be the dominate pathway (28,
29, 31, 32). In our study, we show by H&E large areas of necrosis and by TUNEL assay
large areas of apoptosis in the vehicle group, which are both drastically reduced in the antiCIRP antibody-treated group. Therefore, regardless of which pathway is more prominent we
show that blocking CIRP is beneficial in both ways.
Another DAMP protein HMGB1 has also been shown to be an early mediator of sterile
inflammation (33, 34). Inhibition of HMGB1 activity with neutralizing antibody was also
shown to significantly decrease liver damage after I/R, whereas administration of
recombinant HMGB1 was shown to worsen I/R injury (35). We have previously shown that
CIRP also drives HMGB1 release in macrophages and both bind to TLR4-MD2 complex
and work additively in stimulating inflammatory response (11). It will be interesting to see if
blocking both CIRP and HMGB1 together can provide an additive or synergistic protective
benefit after hepatic I/R injury.
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By attenuating the severe liver damage, anti-CIRP antibody provides a significant survival
advantage to treat animals underwent hepatic I/R. To our knowledge, this represents the first
study in which blocking of CIRP has improved a survival in animals when administered
during the reperfusion phase of hepatic I/R. Antibody belongs to the biologics category in
drug development and has less concern for toxicity when compared to chemical compounds.
Whether the delayed administration of anti-CIRP antibody such as hours or even days after
hepatic I/R still has a beneficial effect for clinical application in treatment needs to be
investigated further. Although administration of anti-CIRP antibody improves the survival
rate to 75%, it still does not provide a complete protection for animals from hepatic I/R
injury. This suggests that factors other than CIRP may contribute to the lethality. Especially,
when the liver undergoes such severe I/R damage, many intracellular components can be
released and serve as DAMPs. It will be a challenge to identify each DAMP's contribution
and its significance in deteriorating the organ; however, this study clearly demonstrates that
CIRP is one of the major mediators to cause the mortality of animals after heptic I/R injury.
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In summary, CIRP is released into the circulation after hepatic I/R and acts as an
endogenous proinflammatory mediator. CIRP can be effectively blocked with anti-CIRP
antibody, which results in attenuating liver injury induced by I/R. It does so by decreasing
the inflammatory response, infiltration of neutrophils, and iNOS-mediated oxidative
damage. In addition, it provides a distinct survival advantage in a lethal model of hepatic
I/R. In the light of these observations, it indicates that extracellular CIRP contributes
significantly to the deterioration of liver after I/R injury and targeting CIRP may provide
another strategy to manage such clinical condition.
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Fig. 1. Increased release of CIRP after hepatic I/R

Western blot analysis of CIRP in the serum samples collected from sham and hepatic I/R
groups at the indicated times after the start of hepatic I/R procedure. Representative blots
against CIRP and Ponceau S red staining (PS red) are shown. Blots were scanned and
quantified with densitometry. Band intensity of CIRP was normalized to the corresponding
band intensity of PS red staining. The value in sham group is designated as 1 for
comparison. Data presented as means ± SE (n=3-4/group) and compared by one-way
ANOVA and SNK method; *p < 0.05 vs. sham.
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Fig. 2. Effect of anti-CIRP antibody treatment on systemic organ injury markers after hepatic
I/R

NIH-PA Author Manuscript

Serum samples were collected at 24 h post-hepatic I/R from sham, vehicle and anti-CIRP
antibody-treated (Anti-CIRP) groups for measuring AST (A), ALT (B), and LDH (C). Data
presented as means ± SE (n=6/group) and compared by one-way ANOVA and SNK
method; *p < 0.05 vs. sham; #p < 0.05 vs. vehicle.
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Fig. 3. Effect of anti-CIRP antibody treatment on tissue damage and cellular architecture in the
liver after hepatic I/R

NIH-PA Author Manuscript

Histologic evaluation of the liver in the sham (A), vehicle (B), and anti-CIRP antibodytreated (C, Anti-CIRP) groups. Liver tissues were harvested 24 h after hepatic I/R,
processed, and then stained with hematoxylin-eosin (H&E). Representative
photomicrographs at 100× magnification. D, Semiquantitative histologic injury score
measuring differences in cytoplasmic vacuolization, cytoplasmic fading, nuclear
condensation, nuclear fading, nuclear fragmentation, and erythrocyte stasis examined on
H&E staining as described in Materials and Methods. Data presented as means ± SE (n=4-5/
group) and compared by one-way ANOVA and SNK method; *p < 0.05 vs. sham; #p < 0.05
vs. vehicle.
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Fig. 4. Effect of anti-CIRP antibody treatment on systemic and local proinflammatory cytokine
IL-6 levels after hepatic I/R
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Serum samples and ischemic liver tissues were collected at 24 h post-hepatic I/R from sham,
vehicle and anti-CIRP antibody-treated (Anti-CIRP) groups. IL-6 protein levels in serum
(A) and liver tissue (B) were determined by enzyme-linked immunosorbent assay. (C) Liver
IL-6 mRNA expression was determined by qPCR analysis and its levels were normalized to
β-actin. The value in sham group is designated as 1 for comparison. Data presented as means
± SE (n=6-7/group) and compared by one-way ANOVA and SNK method; *p < 0.05 vs.
sham; #p < 0.05 vs. vehicle.
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Fig. 5. Effect of anti-CIRP antibody treatment on neutrophil infiltration into the liver after
hepatic I/R
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Ischemic liver tissues were collected at 24 h post-hepatic I/R from sham, vehicle and antiCIRP antibody-treated (Anti-CIRP) groups. (A) MIP-2 mRNA expression was determined
by qPCR analysis and its levels were normalized to β-actin. The value in sham group is
designated as 1 for comparison. Data presented as means ± SE (n=6/group) and compared
by one-way ANOVA and SNK method; *p < 0.05 vs. sham; #p < 0.05 vs. vehicle. Liver
tissues were immunostained against Gr-1, a marker for neutrophil infiltration.
Representative photomicrographs from sham (B), vehicle (C), and anti-CIRP antibodytreated (D, Anti-CIRP) groups at 100× magnification.
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Fig. 6. Effect of anti-CIRP antibody treatment on induction of apoptosis after hepatic I/R

Liver tissues were harvested at 24 h after hepatic I/R and sections subjected to TUNEL
assay to detect DNA fragmentation. Representative TUNEL staining (green fluorescent) and
nuclear counterstaining (blue fluorescent) of liver sections from sham (A), vehicle (B), and
anti-CIRP antibody-treated (C, Anti-CIRP) groups at 100× magnification.
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Fig. 7. Effect of anti-CIRP antibody treatment on iNOS and COX-2 expression after hepatic I/R
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The ischemic portions of the livers were harvested at 24 h post-hepatic I/R for measuring
iNOS (A) and COX-2 (B) mRNA levels by qPCR analysis. iNOS and COX-2 mRNA
expression levels were normalized to β-actin. The value in sham group is designated as 1 for
comparison. Data presented as means ± SE (n=6/group) and compared by one-way ANOVA
and SNK method; *p < 0.05 vs. sham; #p < 0.05 vs. vehicle.
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Fig. 8. Effect of anti-CIRP antibody treatment on survival in a lethal model of hepatic I/R

Survival rates over a 10-day period following 70% hepatic I/R with resection of the
remaining non-ischemic 30% liver tissue are demonstrated for vehicle (black) and anti-CIRP
antibody treatment (gray). Survival rates were analyzed by the Kaplan-Meier estimator
using a log-rank test. *p < 0.05 vs. vehicle.
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